{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:08:42Z","timestamp":1783922922190,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023-068"],"award-info":[{"award-number":["2023-068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["KXJZ[2024]004"],"award-info":[{"award-number":["KXJZ[2024]004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370166"],"award-info":[{"award-number":["82370166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960036"],"award-info":[{"award-number":["81960036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010828","name":"Department of Education of Guizhou Province","doi-asserted-by":"publisher","award":["KXJZ[2024]004"],"award-info":[{"award-number":["KXJZ[2024]004"]}],"id":[{"id":"10.13039\/501100010828","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118064","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:59:28Z","timestamp":1778817568000},"page":"118064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia"],"prefix":"10.1016","volume":"251","author":[{"given":"Anran","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-3752","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118064_b0005","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for Relapsed\/Refractory Acute Myeloid Leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0010","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.bcp.2026.118064_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2026.118064_b0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/jcm4040665","article-title":"Current approaches in the treatment of relapsed and refractory acute myeloid leukemia","volume":"4","author":"Ramos","year":"2015","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118064_b0025","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1349-7006.2007.00581.x","article-title":"Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides","volume":"98","author":"Yoshio","year":"2007","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.118064_b0030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bcp.2011.12.042","article-title":"ABC Transporters and their Role in Nucleoside and Nucleotide Drug Resistance","volume":"83","author":"Manuscript","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118064_b0035","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat Cancer."},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/mol.105.021543","article-title":"The role of human nucleoside transporters in cellular uptake of 4\u2032-Thio-\u03b2-D-arabinofuranosylcytosine and \u03b2-D-arabinosylcytosine","volume":"70","author":"Clarke","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118064_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/dmd.119.089334","article-title":"Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines","volume":"48","author":"Bj\u00e5nes","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118064_b0050","first-page":"4219","volume":"24","author":"Amal","year":"2023","journal-title":"Association of Cytidine Deaminase Polymorphism with Capecitabine Effectiveness in Breast Cancer Patients."},{"issue":"5","key":"10.1016\/j.bcp.2026.118064_b0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/17425255.2015.985648","article-title":"Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs","volume":"11","author":"Serdjebi","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118064_b0060","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/0008-5472.CAN-03-2456","article-title":"The Role of Cytidine Deaminase and GATA1 Mutations in the increased Cytosine Arabinoside Sensitivity of down Syndrome Myeloblasts and Leukemia Cell Lines","volume":"64","author":"Ge","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118064_b0065","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood.V90.5.1968","article-title":"Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based primi","volume":"90","author":"Jahns-Streubel","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118064_b0070","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1046\/j.1365-2141.1998.01084.x","article-title":"Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia","volume":"103","author":"Schr\u00f6der","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118064_b0075","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/bloodadvances.2017014126","article-title":"CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine","volume":"2","author":"Fanciullino","year":"2018","journal-title":"Blood Adv."},{"issue":"7563","key":"10.1016\/j.bcp.2026.118064_b0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature14948","article-title":"CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer","volume":"524","author":"Zauri","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118064_b0085","article-title":"Oral decitabine\u2013cedazuridine in acute myeloid leukaemia","volume":"1674\u20136","author":"Bouligny","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0090","doi-asserted-by":"crossref","first-page":"18206","DOI":"10.1038\/s41598-024-69347-x","article-title":"Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment","volume":"14","author":"Karatkevich","year":"2024","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.118064_b0095","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s12276-022-00836-7","article-title":"DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor\u2013resistant lung cancer therapy","volume":"54","author":"Heo","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118064_b0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cell.2011.03.022","article-title":"Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain","volume":"145","author":"Guo","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.118064_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1095\/biolreprod.111.096073","article-title":"The Involvement of 5-Hydroxymethylcytosine in active DNA Demethylation in Mice1","volume":"86","author":"Zhang","year":"2012","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.bcp.2026.118064_b0110","first-page":"534","article-title":"Letter DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines. Protein Cell","author":"Cell","year":"2023","journal-title":"Protein"},{"issue":"10","key":"10.1016\/j.bcp.2026.118064_b0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-023-04932-3","article-title":"Metformin induces tolerogenicity of dendritic cells by promoting metabolic reprogramming","volume":"80","author":"Liu","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2026.118064_b0120","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2147\/DDDT.S138371","article-title":"Schiff base derived from thiosemicarbazone and anthracene showed high potential in overcoming multidrug resistance in vitro with low drug resistance index","volume":"11","author":"Bai","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2162-3619-2-20","article-title":"Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia","volume":"2","author":"Momparler","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hon.2191","article-title":"High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?","volume":"34","author":"Wolach","year":"2016","journal-title":"Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118064_b0135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","article-title":"Clinical pharmacokinetics of cytarabine formulations","volume":"41","author":"Hamada","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118064_b0140","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.2147\/CMAR.S181299","article-title":"Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase II\u03b1 as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin","volume":"10","author":"Kulsoom","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.118064_b0145","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s44318-024-00108-2","article-title":"Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS","volume":"43","author":"Carnie","year":"2024","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118064_b0150","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000513696","article-title":"Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine","volume":"144","author":"Wu","year":"2021","journal-title":"Acta Haematol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118064_b0155","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118064_b0160","doi-asserted-by":"crossref","first-page":"ix95","DOI":"10.1093\/annonc\/mdz427.014","article-title":"Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine","volume":"30","author":"Sun","year":"2019","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2026.118064_b0165","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1093\/nar\/gks707","article-title":"Deoxycytidine kinase regulates the G2\/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage","volume":"40","author":"Yang","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118064_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1626-x","article-title":"Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine","volume":"10","author":"Levin","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118064_b0175","first-page":"1187","author":"Article","year":"2017","journal-title":"Enhanced Sensitivity to Glucocorticoids in Cytarabine- Resistant AML."},{"issue":"23","key":"10.1016\/j.bcp.2026.118064_b0180","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.18632\/oncotarget.26784","article-title":"The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes","volume":"10","author":"Murakami","year":"2019","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bcp.2026.118064_b0185","first-page":"139","article-title":"Role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity","volume":"176","author":"Cortes-Penfield","year":"2017","journal-title":"Physiol. Behav."},{"issue":"P2","key":"10.1016\/j.bcp.2026.118064_b0190","article-title":"Nanobiotechnology-based strategies in alleviation of chemotherapy-mediated cardiotoxicity","volume":"238","author":"Luo","year":"2023","journal-title":"Environ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.118.255984","article-title":"The MitoNEET ligand NL-1 mediates antileukemic activity in drug-resistant B-cell acute lymphoblastic leukemia","volume":"370","author":"Geldenhuys","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118064_b0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ehm.12.68","article-title":"Elacytarabine: Lipid vector technology under investigation in acute myeloid leukemia","volume":"6","author":"Keane","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"May","key":"10.1016\/j.bcp.2026.118064_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jconrel.2022.05.063","article-title":"Strategies for persistent retention of macromolecules and nanoparticles in the blood circulation","volume":"350","author":"Takakura","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118064_b0210","first-page":"2147","author":"Park","year":"2017","journal-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy."},{"key":"10.1016\/j.bcp.2026.118064_b0215","doi-asserted-by":"crossref","unstructured":"Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. 2020;597\u2013609.","DOI":"10.1056\/NEJMoa1914609"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:30:43Z","timestamp":1783920643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S0006295226003977"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118064","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118064"}}